New body mass index for predicting prognosis in patients with antineutrophil cytoplasmic antibody-associated vasculitis

被引:4
|
作者
Pyo, Jung Y. [1 ]
Ahn, Sung S. [1 ]
Lee, Lucy E. [1 ]
Song, Jason J. [1 ,2 ]
Park, Yong-Beom [1 ,2 ]
Lee, Sang-Won [1 ,2 ]
机构
[1] Yonsei Univ, Dept Internal Med, Div Rheumatol, Coll Med, 50-1 Yonsei Ro, Seoul 03722, South Korea
[2] Yonsei Univ, Inst Immunol & Immunol Dis, Coll Med, Seoul, South Korea
关键词
antineutrophil cytoplasmic antibody-associated vasculitis; conventional BMI; new BMI; poor outcomes; underweight; INTENSIVE-CARE-UNIT; HOSPITAL MORTALITY; WEIGHT-LOSS; MALNUTRITION; OUTCOMES;
D O I
10.1002/jcla.24357
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Objectives Body mass index (BMI) is a known indicator of all-cause mortality. However, conventional BMI does not reflect the three-dimensional human body. To overcome this limitation, a new BMI has been proposed that provides a closer approximation of real human body shape. This study investigated the associations between the new BMI and poor outcomes in patients with antineutrophil cytoplasmic antibody-associated vasculitis (AAV). Method We retrospectively reviewed the medical records of 242 patients with AAV in a single tertiary medical center. Based on the new BMI, the patients were categorized into four groups: underweight (<18.5 kg/m(2.5)), healthy weight (18.5 to <25.0 kg/m(2.5)), overweight (25.0 to <30.0 kg/m(2.5)), and obese (>= 30.0 kg/m(2.5)). The association among the new BMI and death, relapse, end-stage renal disease (ESRD) development, cerebrovascular accident, and cardiovascular disease was analyzed. Results The underweight group, according to the new BMI, had higher hazard ratios (HRs) for all-cause mortality (HR: 3.180, 95% confidence interval [CI]: 1.134-8.922, p = 0.028), relapse (HR: 2.141, 95% CI: 1.019-4.368, p = 0.036), and ESRD development (HR: 2.729, 95% CI: 1.190-6.259, p = 0.018) than the healthy weight group. However, according to the conventional BMI, there were no differences in the risks for all poor outcomes between the underweight and healthy weight groups. Multivariate logistic regression analysis demonstrated that being underweight, according to the new BMI, was an independent risk factor for all-cause mortality (HR: 5.285; 95% CI: 1.468-19.018; p = 0.011). Conclusion Being underweight, according to the new BMI, is associated with poor outcomes in patients with AAV.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] The Expanding Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Armamentarium
    Mcgovern, Dominic P.
    Jones, Rachel B.
    Jayne, David R. W.
    Smith, Rona M.
    DRUGS, 2025,
  • [22] Nailfold videocapillaroscopy in antineutrophil cytoplasmic antibody-associated vasculitis
    Sullivan, Megan M.
    Abril, Andy
    Aslam, Nabeel
    Ball, Colleen T.
    Berianu, Florentina
    ARTHRITIS RESEARCH & THERAPY, 2024, 26 (01)
  • [23] Outcome measures for antineutrophil cytoplasmic antibody-associated vasculitis
    Tomasson, Gunnar
    CURRENT OPINION IN RHEUMATOLOGY, 2015, 27 (01) : 38 - 44
  • [24] Efficacy of the fibrosis index for predicting end-stage renal disease in patients with antineutrophil cytoplasmic antibody-associated vasculitis
    Pyo, Jung Yoon
    Ahn, Sung Soo
    Lee, Lucy Eunju
    Choe, Ha Na
    Song, Jason Jungsik
    Park, Yong-Beom
    Lee, Sang-Won
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2021, 75 (04)
  • [25] Maintenance Immunosuppression in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
    Cattran, Daniel C.
    Hladunewich, Michelle A.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2011, 57 (06) : 818 - 821
  • [26] Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis
    McGregor, JulieAnne G.
    Hogan, Susan L.
    Kotzen, Elizabeth S.
    Poulton, Caroline J.
    Hu, Yichun
    Negrete-Lopez, Roberto
    Kidd, Jason M.
    Katsanos, Suzanne L.
    Bunch, Donna O.
    Nachman, Patrick H.
    Falk, Ronald J.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2015, 30 : i123 - i131
  • [27] The Expanding Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Armamentarium
    Mcgovern, Dominic P.
    Jones, Rachel B.
    Jayne, David R. W.
    Smith, Rona M.
    DRUGS, 2025, 85 (03) : 325 - 341
  • [28] Current Landscape of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
    Lally, Lindsay
    Spiera, Robert
    RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2015, 41 (01) : 1 - +
  • [29] AVACOPAN: A New Adjunctive Therapy for Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
    Garg, Jasmine
    Frishman, William H.
    CARDIOLOGY IN REVIEW, 2023, 31 (01) : 3 - 6
  • [30] Renal Involvement in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
    Zonozi, Reza
    Niles, John L.
    Cortazar, Frank B.
    RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2018, 44 (04) : 525 - +